Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1

Status

Recruiting 2Active not recruiting 2Completed 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 9Genitourinary 6Head & Neck 5Gynecologic 4Thoracic 3Sarcoma 2Dermatologic 2CNS 2Tumor-Agnostic 1Other solid neoplasm 1Lymphoid 1

Conditions

Nasopharyngeal Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Nasopharyngeal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 89pembrolizumab 83Magnetic Resonance Spectroscopy 47Radiotherapy, Intensity-Modulated 41Specimen Handling 37Cetuximab 37Carboplatin 37Radiotherapy 36Nivolumab 29Paclitaxel 25Platinum 23Radiation 22Docetaxel 22Gemcitabine 21Biopsy 211,2-diaminocyclohexaneplatinum II citrate 21Surveys and Questionnaires 17Fluorouracil 14toripalimab 13Standard of Care 13Taxes 11Cyclophosphamide 10cemiplimab 9atezolizumab 9X-Rays 9Surgical Procedures, Operative 9Ipilimumab 9Immunoglobulin G 9Drug Therapy 9Capecitabine 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
spartalizumab × Head & Neck × 90 days × Clear all
NCT06802835 2026-05-11

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 1/2 Recruiting
148 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT05201859 2026-05-07

Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 2 Active not recruiting
150 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT06475300 2026-05-06

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2 Recruiting
570 enrolled
Head & NeckThoracic

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT05213884 2026-04-24

The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC

Chongqing University Cancer Hospital

Phase 2 Completed
39 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04080804 2026-04-22

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

University of Pittsburgh

Phase 2 Active not recruiting
80 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡